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Obesity and its associated metabolic abnormalities, including insulin resistance and type 2 diabetes, have reached epidemic proportions, adversely affecting health and global mortality rates 1 . Multiple factors contribute to reduced insulin sensitivity, but chronic inflammation in VAT, which results in local and systemic increases in proinflammatory cytokines and adipokines is a major driver 2, 3 . One of these drivers, macrophage infiltration of VAT, is a key event in the establishment of adipose inflammation and insulin resistance 4, 5 . Classically activated, or CD11c + CD206 − M1 macrophages, are elevated in VAT of DIO mice and produce proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and . T cells are also major participants in VAT inflammation, with proinflammatory CD8 + T cells and interferon-γ (IFN-γ)-producing CD4 + T cells contributing to inflammation, glucose intolerance and insulin resistance in DIO mice [9] [10] [11] . On the contrary, VAT-resident forkhead box P3-expressing (Foxp3 + ) regulatory T cells, which produce IL-10 and TGF-β, as well as IL-4-and IL-13-secreting type 2 helper T cells (T H 2 cells), can have protective roles [11] [12] [13] . Notably, the clonal diversity of VAT T cells is highly restricted, which suggests that an active adaptive immune response expanding potentially autoimmune T cells occurs in obese VAT [11] [12] [13] [14] .
In contrast to macrophages and T cells, little is known about the role of B cells in the development of insulin resistance, despite evidence that such cells are recruited to adipose tissue shortly after the initiation of a high-fat diet (HFD) 15 and that their activation is increased in people with type 2 diabetes 16 . Here we show that B cells and IgG are key pathogenic effectors in the development of obesityassociated insulin resistance and glucose intolerance, but not of excess weight gain, in DIO mice. Manipulation of B cells, antibodies or their Fc (fragment crystallizable) receptors may yield promising new therapies for the management of insulin resistance and its associated comorbidities.
RESULTS

B cells and antibodies in DIO mice
We analyzed early immune cell infiltration into epididymal VAT of 6-week-old C57BL/6 mice fed a high-fat diet (60% kcal) for several weeks and compared the immune cell composition to age-matched C57BL/6 mice that were fed a normal chow diet (NCD) (Fig. 1a) . HFD induced a significant accumulation of B cells in VAT by 4 weeks that was maintained after 6-12 weeks on HFD (Fig. 1a) . This increase in B cell numbers included total B cells, B1a cells and B2 cells. Total T cell numbers were also increased by 4 weeks, and absolute numbers continued to rise while the mice were on a HFD, consistent with previous reports 11, 15, 17 . Despite the increase in absolute B cell numbers in DIO VAT, the relative proportions of B1 and non-B1 subsets were unchanged (Fig. 1a) . However, DIO VAT had increased numbers and proportions of class-switched mature B cells, such as IgG + cells, a pattern suggesting an actively progressing immune process in this fat depot of obese mice (Fig. 1b) .
To investigate the effects of HFD on systemic B cells, we analyzed spleens from age-matched 12-to 18-week-old HFD-fed and NCD-fed Chronic inflammation characterized by T cell and macrophage infiltration of visceral adipose tissue (VAT) is a hallmark of obesity-associated insulin resistance and glucose intolerance. Here we show a fundamental pathogenic role for B cells in the development of these metabolic abnormalities. B cells accumulate in VAT in diet-induced obese (DIO) mice, and DIO mice lacking B cells are protected from disease despite weight gain. B cell effects on glucose metabolism are mechanistically linked to the activation of proinflammatory macrophages and T cells and to the production of pathogenic IgG antibodies. Treatment with a B cell-depleting CD20 antibody attenuates disease, whereas transfer of IgG from DIO mice rapidly induces insulin resistance and glucose intolerance. Moreover, insulin resistance in obese humans is associated with a unique profile of IgG autoantibodies. These results establish the importance of B cells and adaptive immunity in insulin resistance and suggest new diagnostic and therapeutic modalities for managing the disease.
nAture medicine VOLUME 17 | NUMBER 5 | MAY 2011 6 1 1 mice. No significant differences were seen in total spleen cell counts or the percentages of naive IgD + B cells, marginal zone B cells or IgM + IgD − follicular B cells (Fig. 1c) . However, in contrast to DIO VAT, DIO spleens contained reduced percentages of IgM + IgD − cells (Fig. 1c) . Consistent with these results, total spleen B cells from DIO mice showed reduced spontaneous production of IgM antibody but elevated IgG secretion (Fig. 1d) , suggesting that HFD induces a systemic humoral immune response. We confirmed this systemic response by comparing concentrations of immunoglobulin isotypes in serum and VAT of NCD and DIO mice. DIO mice had reduced concentrations of serum IgA and an increase in serum IgG2c (Fig. 1e) , a proinflammatory isotype present in C57BL/6, C57BL/10 and nonobese diabetic mice 18 . VAT lysates from HFD-fed mice had higher concentrations of IgM compared to IgG and a marked (more than threefold) enrichment in proinflammatory IgG2c (Fig. 1f) . Notably, antibody staining in VAT showed a preferred localization of IgG and IgM to regions of crown-like structures (CLSs) (Fig. 1g) 19, 20 . Many of these stained cells were at the interface of large mononucleate and multinucleate giant macrophages and dying adipocytes inside the CLSs. CLSs appeared bathed in tissue fluid enriched for IgM and IgG, whereas the remaining fat tissue showed either very weak or no Ig staining. Enrichment of IgG and IgM in CLSs implicates the involvement of antibodies in the clearance of dying adipocytes 19, 20 .
B cells are pathogenic in glucose metabolism in DIO mice
To assess the effect of B cells on the regulation of obesity and insulin resistance, we investigated C57BL/6 immunoglobulin µ heavy-chain knockout mice (B null ) which do not produce mature B cells, for their response to HFD started at 6 weeks of age 21 . After 8 weeks of HFD, there was no difference in body weight or VAT adipocyte size (Fig. 2a,b) , but DIO B null mice had a lower ratio of VAT to subcutaneous adipose tissue (SAT) fat pad weight than DIO WT mice (Fig. 2c) .
Compared with HFD-fed WT mice, 16-week-old HFD-fed B null mice had lower fasting glucose (Fig. 2d) and improved glucose tolerance (Fig. 2e) . Similarly, 16-week-old HFD-fed B null mice had reduced fasting insulin (Fig. 2f) and improved insulin sensitivity upon insulin challenge (Fig. 2g) . B cell deficiency did not affect weight, fasting glucose, fasting insulin or glucose and insulin tolerance in NCD mice (Fig. 2a,d-g ), suggesting that metabolic influences of B cells require a HFD. To confirm that abnormal glucose metabolism in HFD-fed mice is directly attributable to B cells, age-matched 16 to 18 weeks old HFD-fed B null mice were reconstituted intraperitoneally (i.p.) with 1 × 10 7 total B cells from spleens of DIO WT mice. After 2-3 weeks, B cells reconstituted primarily in VAT over spleen (Supplementary Fig. 1a ) and produced low concentrations of serum antibody (Supplementary Fig. 1b) . B cell transfer did not affect total weight (Fig. 2h) . However, B null mice reconstituted with B cells from DIO mice had worsened glucose tolerance (Fig. 2h) and higher fasting insulin levels (Fig. 2h) compared to control B null recipients. B cells from NCD mice did not promote impairment in glucose homeostasis (Fig. 2i) , despite similar reconstitution profiles as B cells from DIO mice (Supplementary Fig. 1c) , thus indicating that development of pathogenic B cells requires exposure to a HFD. Collectively, these results suggest a pathogenic role for HFD-derived B cells in the promotion of obesityassociated insulin resistance and glucose intolerance. DIO B null mice show reduced immune cell activation in VAT Inflamed adipose tissue is a key feature of insulin resistance. As B cells reside in VAT and worsen metabolic parameters upon adoptive transfer, we examined the possibility that these cells promote inflammation in VAT. VAT total T cell and macrophage counts were similar in DIO WT and DIO B null mice (Fig. 3a) , but DIO B null mice had fewer proinflammatory M1 macrophages (Fig. 3b) . To examine the functional profiles of these immune cells, we measured cytokines known to affect insulin resistance (TNF-α and IFN-γ) 9, 22, 23 . The supernatants of total VAT stromal vascular cell (SVC) cultures from DIO B null mice had lower concentrations of IFN-γ compared to DIO WT mice (Fig. 3c) . The number of VAT-associated CD8 + T cells producing IFN-γ from DIO B null mice was approximately 30% less compared to DIO WT mice (Fig. 3d) . DIO B null CD8 + T cells also expressed less of the cytotoxic activation marker CD107a (Fig. 3d) . IFN-γ expression was variable in CD4 + T cells of DIO WT and B null mice ( Supplementary Fig. 2a ). Supernatants of VAT SVC cultures from DIO B null mice also contained less TNF-α compared to DIO WT mice (Fig. 3e) . Macrophages, especially M1 macrophages, are a major source of TNF-α, and its decrease in DIO B null VAT is partly attributable to reduced numbers of macrophages producing this cytokine (Fig. 3e) . In addition, fewer DIO B null VAT macrophages expressed co-stimulatory CD86, consistent with an overall decrease in macrophage activation in these mice (Fig. 3f) .
Analysis of serum revealed that concentrations of resistin and plasminogen activator inhibitor-1 (PAI-1), both previously associated with insulin resistance 24, 25 , were markedly lower in DIO B null than DIO WT mice ( Supplementary Fig. 2b ). This result suggests that in DIO mice, B cells induce systemic as well as local (VAT) inflammation.
B cells modulate VAT associated T cells in vivo
B cell functions are influenced by other lymphocyte populations (especially T cells) and vice versa 26 . To begin to discern a role for T cells in facilitating B cell-mediated glucose intolerance, we reconstituted 16-week-old HFD-fed C57BL/6 recombinase activating gene-1-null (RAG-1 null ) mice, which lack lymphocytes, with 1 × 10 7 total DIO splenic B cells. After 2 weeks, despite reconstitution ( Supplementary  Fig. 3 ), the B cells did not worsen fasting glucose, insulin, or glucose tolerance-contrasting with transfers into DIO B null mice-thereby suggesting that B cells require other lymphocytes to fully promote the impairment of metabolic parameters (Fig. 3g) .
B cells can activate CD8 + and CD4 + T cells by presenting antigen via major histocompatibility complex (MHC) class I and MHC class II, respectively. To determine whether B cell-dependent T cell activation is involved in the promotion of glucose intolerance, we reconstituted age-matched 16-week-old HFD-fed B null mice with 1 × 10 7 purified (> 95%) splenic B cells from either DIO WT mice, or DIO mice lacking MHC class I (C57BL/6 MHC-I null ) or MHC class II (C57BL/6 MHC-II null ). Two weeks after i.p. transfer, CD19 + B cells had successfully reconstituted VAT but not spleen in the DIO B null mice ( Fig. 3h and Supplementary Fig. 1a ). There were no significant differences in weight after adoptive transfer (Fig. 3i) . However, in contrast to recipients of B cell grafts from WT mice, recipients of B cells from either MHC-I null or MHC-II null mice did not develop glucose intolerance or hyperinsulinemia (Fig. 3i) . Improved glucose homeostasis in mice receiving MHC null B cells compared to mice receiving WT B cells,was associated with reduced total VAT SVC production of IFN-γ (Fig. 3j) , attributable to either reduced numbers of VAT CD8 + T cells producing IFN-γ (MHC-I null recipients, Fig. 3j ) or reduced numbers of VAT CD4 + T cells producing IFN-γ (MHC-II null recipients, Fig. 3j ). The data show that B cell modulation of VAT T cells occurs in an MHC-dependent manner, probably through B cell antigen presentation to T cells, and that both MHC class I (CD8 + T cells) and class II (CD4 + T cells) are needed for the B cells to maximally affect glucose tolerance in the adoptive transfer model.
IgG antibodies are mediators of glucose intolerance
In addition to their functions in the modulation of T cell activation, B cells produce antibodies, which are known regulators of immune function 27 . Because obesity is associated with increased IgG production and IgG + B cells in VAT, as well as with increased concentrations of systemic and local IgG2c (Fig. 1b-f) , we next investigated a possible role of IgG in glucose intolerance. We purified IgG (>98% pure) from pooled sera of 16-to 24-week-old HFD-fed (HFD IgG) or NCDfed (NCD IgG) WT mice and injected it i.p. into age-matched DIO B null mice. One week after transfer, IgG was present in the serum of all recipient mice (Fig. 4a) . Within this time frame, antibody transfer had no effect on body weight (Fig. 4b) . However, HFD IgG induced a dramatic worsening of glucose tolerance, which was absent in NCD IgG recipients (Fig. 4c) ; this suggests that pathogenic IgG specificities are induced during the course of a HFD but not during NCD. This antibody-mediated metabolic effect was associated with worsened fasting insulin, a hallmark of insulin resistance, in HFD IgG recipient mice compared to NCD IgG recipient mice (Fig. 4c) . Transferred antibodies also localized to VAT, where they were in close association with CLSs (Supplementary Fig. 4a ). The effects of antibody transfer on glucose metabolism were transient and, as expected on the basis of normal IgG half-life, by 4 weeks after transfer there was no difference in glucose tolerance or fasting insulin between IgG and control recipients (Fig. 4d) .
To determine whether pathogenic antibodies arise early after the initiation of HFD, we purified IgG from 9-to12-week-old HFD-fed mice (early HFD IgG), as well as from 20-to 24-week-old HFDfed mice (late HFD IgG), and injected each type separately i.p. into 20-week-old HFD-fed B null mice. We observed a much stronger effect on glucose tolerance and fasting insulin concentrations with late HFD IgG compared to early HFD IgG; this suggests a possible role for affinity maturation of antibody or late unmasking of HFD antigen in the process (Fig. 4e) . To investigate whether HFD IgG-induced disease depends on HFD exposure in recipient mice, we transferred HFD IgG (IgG purified from 16-to 24-week-old HFD-fed C57BL/6 mice) into 6-week-old lean mice. One week after transfer, there was little change in weight, glucose tolerance or fasting insulin levels (Fig. 4f) , thus indicating that the effects of HFD IgG on glucose metabolism are dependent on the recipient's exposure to HFD.
To investigate the mechanism by which HFD IgG induces glucose intolerance, we first examined its effects on VAT and systemic inflammation. HFD IgG recipient mice had higher concentrations of TNF-α in VAT SVC cultures and more pronounced M1 macrophage polarization in VAT when compared to controls (Fig. 4g) . In addition, these mice had elevated serum concentrations of proinflammatory mediators including monocyte chemoattractant protein-3, IL-6 and granulocytemacrophage colony-stimulating factor (Supplementary Fig. 4b ). IgG antibodies, through their Fc portions, can bind Fcγ receptors (FcγRs) on macrophages and directly induce macrophage oxidative burst, cytotoxicity and proinflammatory cytokine production 27 . To determine whether the observed effect of HFD IgG antibodies on glucose intolerance is mediated through their Fc components, we generated F(ab′) 2 fragments from HFD IgG and compared their effect on glucose metabolism to that of intact HFD IgG. One week after i.p. transfer into age-matched DIO B null mice, HFD IgG F(ab′) 2 did not worsen glucose tolerance and fasting insulin compared to intact HFD IgG, thereby indicating that the pathogenic properties of HFD IgG are mediated through the Fc region (Fig. 4h) . Consistent with these findings, macrophages isolated from VAT of DIO B null mice stimulated with HFD IgG show an Fc-dependent increase in TNF-α production in vitro (Fig. 4i) . In contrast to HFD IgG, HFD IgM had no effect on metabolic parameters (Fig. 4j) . These data point to an unexpected pathogenic role for HFD-induced IgG antibody in promoting glucose intolerance and insulin resistance.
Insulin resistance is linked to distinct profiles of IgG As HFD IgG can exert pathologic effects on insulin resistance in obese mice, we next examined whether IgG autoantibodies are present in insulin-resistant humans and, if so, whether they recognize a distinct cluster of antigenic targets. We probed Invitrogen ProtoArray V5.0 chips containing more than 9,000 spotted antigens with serum from 32 age-and weight-matched, overweight to obese, otherwise healthy, male human subjects (Supplementary Table 1 ). The two groups of subjects differed only in their insulin sensitivities, as determined by a modified insulin-suppression test, and individuals were defined as either insulin resistant or insulin sensitive on the basis of their steadystate plasma glucose concentration. We identified 122 IgG targets that differentially segregated with insulin resistance, whereas 114 targets segregated with insulin sensitivity. The ten antigens that were most highly associated with either insulin resistance or insulin sensitivity in our obese male subjects are shown in Table 1 . Antibodies to the top three targets segregating with insulin resistance were validated in these subjects by western blotting (Supplementary Fig. 5 ). Notably, in both groups the antigens are mostly intracellular proteins, many of which are expressed ubiquitously in tissues including immune cells, pancreas, nervous tissues, muscle or fat.
B cell depletion ameliorates metabolic disease
To determine whether the manipulation of B cells can be exploited therapeutically in obesity-related insulin resistance, we treated HFD-fed WT mice with a depleting antibody specific to mouse CD20 (MB20-11; ref. 28) . We injected antibody 6-7 weeks after initiation of HFD and maintained the mice on an HFD. B cells, which were depleted by >95% locally in VAT and systemically in spleen 8 d after injection (Fig. 5a) , began to repopulate tissues by day 28 after injection; nonetheless, there was still >70% depletion. CD20-specific monoclonal antibody (mAb) treatment had no effect on weight (Fig. 5b) or total serum concentrations of IgG or IgM (Fig. 5c ) by 28 d after injection. However, treated mice showed improvements compared to control-treated mice in fasting glucose (Fig. 5d), glucose tolerance (Fig. 5e) and fasting insulin (Fig. 5f) . Improved glucose tolerance persisted for more than 40 d and diminished with the return of B cells (Supplementary Fig. 6a ). Consistent with a role for B cells in altering the local VAT cytokine milieu, VAT SVCs of treated mice showed reduced concentrations of the key inflammatory mediators IFN-γ (Fig. 5g) and TNF-α (Fig. 5h) ; the latter change was attributable, at least partly, to reduced production by macrophages (Fig. 5i) . Notably, IgG from CD20 mAb-treated mice was unable to transfer metabolic disease (Supplementary Fig. 6b) , suggesting that CD20-specific mAb treatment may lead to alterations in IgG function in addition to its other effects on B cells 29 .
DISCUSSION
We discovered a fundamental role for B cells in the pathogenesis of obesity-associated insulin resistance. Previous studies have identified other immune cells as metabolic controllers with pathogenic potential in obesity [9] [10] [11] . In healthy nonobese individuals, VAT-resident regulatory T cells and T H 2 cells have a beneficial effect by reducing VAT inflammation. During DIO, these cells are overwhelmed by proinflammatory CD8 + and T H 1 cells, which promote insulin resistance and glucose intolerance 11 . B lymphocytes can now be added to the list of immune cells participating in this process, in which they activate CD8 + and T H 1 cells and release pathogenic antibodies.
Consistent with a previous report 15 , we show that B cell accumulation in VAT occurs early (by 4 weeks) after initiation of HFD. B cells worsen glucose tolerance, in part, by inducing MHC-dependent pro-inflammatory cytokine production by both CD4 + and CD8 + T cells. Similar mechanisms occur in models of infection, cancer 30 and autoimmunity 28 . As B and T cells are recruited early to VAT in response to HFD 10, 15 , the data support a role for B cells in modulating T cell function in DIO VAT. Alternatively, T cells may function by inducing IgG class switching in B cells. Indeed, we observed elevated concentrations of proinflammatory IgG2c in serum and VAT of DIO mice. Class switching could also be influenced by lipids in the HFD VAT environment acting directly through TLRs on B cells. It is also possible that cytokines or antibodies produced by B cells can directly interact with and affect insulin sensitivity in adipocytes.
B cells also exacerbate metabolic disease through production of IgG. Although autoantibodies have not been previously recognized as having a crucial role in type 2 diabetes, an estimated 10% of people with type 2 diabetes have antibodies to islet cell antigens, and these antibodies are correlated with the need for insulin therapy 31 . Almost one-third of people with advanced type 2 diabetes have autoantibodies that inhibit endothelial cell function 32 . The presence of antibodies to glial fibrillary acidic protein (GFAP), which predicts insulin resistance as shown by our array ( Table 1) , is also reported at higher rates in type 2 diabetes 33 .
We show that transfer of IgG from DIO WT mice to DIO B null mice induces rapid local and systemic changes in inflammatory cytokine production, and that it changes VAT macrophages to a proinflammatory M1 phenotype. These effects required exposure to HFD, suggesting that factors related to diet, possibly including diet-induced conditioning or induction of target autoantigens, are required for antibodies to exert their effects on glucose metabolism. Furthermore, we show that HFD IgG antibodies induce insulin resistance through an Fc-mediated process. As DIO VAT is a site of increased apoptotic and necrotic load, and because antibodies concentrate in regions of VAT CLSs, it is conceivable that interactions between antibodies and FcRs on macrophages occur in VAT and promote clearance of apoptotic and necrotic debris and inflammation 34, 35 . Identification of the precise FcR responsible for IgG effects on glucose metabolism warrants further investigation. Antibodies also fix complement; recently, the complement protein C3a and its receptor C3aR on macrophages were identified as key mediators of insulin resistance 36 .
We further show that insulin resistance in obese humans is linked to autoantibodies directed against a specific profile of self antigens. Antibodies to one of the top three antigens linked to insulin resistance, GFAP, occur in approximately 30% of people with type 2 diabetes 33 . Notably, we detected antibodies to Golgi SNAP receptor complex member-1 (GOSR1) in more than 70% of obese insulin resistant males. GOSR1 is an essential component of the Golgi SNAP receptor complex, where it functions in trafficking proteins between the endoplasmic reticulum and the Golgi 37 . It is unknown whether expression of this protein changes in response to endoplasmic reticulum stress, which is thought to be a prominent initiator of insulin resistance 38 . Our array data also show distinct antigenic targets associated with insulin sensitivity, thereby raising the possibility that some IgG antibodies may be protective. It will be crucial to validate antigenic targets in larger cohorts.
Finally, we show that depletion of B cells with a CD20-targeting mAb early in disease has therapeutic benefit in abnormal glucose metabolism. These results are consistent with a role for B cells early in disease pathogenesis, similar to observations in several autoimmune diseases 39 . Recently, CD20-specific mAb was used in the treatment of atherosclerotic lesions in apoliprotein E-deficient (Apoe −/− ) and low-density lipoprotein receptor-deficient (Ldlr −/− ) mice 40 . In CD20-specific mAb experiments, beneficial anti-inflammatory effects are linked to reduced T cell activation. Accordingly, we observed reduced concentrations of proinflammatory IFN-γ and TNF-α in VAT after CD20-specific mAb treatment.
Consistent with other reports, total serum levels of IgM and IgG after CD20-specific mAb treatment were not drastically changed despite a prominent therapeutic benefit 41 . One possible explanation for this finding is that in our studies, CD20-specific mAb was administered by 6-7 weeks after HFD, just a few weeks after B cells substantially infiltrate VAT. Because HFD IgG became more pathogenic with longer exposure to HFD, we hypothesized that the antibodies present after early treatment were not fully pathogenic. This was verified by the inability of antibodies from mice treated with CD20-specific mAb to transfer metabolic disease. The lack of pathogenicity of HFD IgG from CD20-specific mAb-treated mice at this time point could be a result of reduced affinity maturation, reduced class switching or both 41 .
Rituximab, a mAb specific for human CD20 and used in the treatment of rheumatoid arthritis as well as in B cell malignancies, can cause both hyperglycemia and severe hypoglycemia 42 . Other B celland antibody-modulating agents are either approved for human use or in clinical trials, including intravenous immunoglobulin (IvIg), transmembrane activator and calcium modulator and cyclophilin ligand (TACI) fusion proteins, and antibodies or small-molecule inhibitors to CD19, CD22, CD79a and b, B lymphocyte stimulator (BLyS), spleen tyrosine kinase (Syk) and a proliferation-inducing ligand (APRIL). Our findings suggest new possible uses for such agents, and agents that modulate FcR function and signaling, in the management of obesity-related abnormalities in glucose metabolism.
Collectively, our data support a model wherein early recruitment of B cells promotes VAT T cell activation and proinflammatory cytokine production, which potentiate M1 macrophage polarization and insulin resistance. B cells can also exert their detrimental effects systemically through the production of pathogenic IgG antibodies, which target distinct clusters of self proteins. Comparative mass sequencing of T and B cell antigen receptors in obesity-related insulin resistance
